Studying low white blood cells from palbociclib in metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at a drug called palbociclib, which is a targeted therapy for a certain type of breast cancer. It aims to understand how often it causes low white blood cell counts (neutropenia) and how that affects treatment success. If you have metastatic HR+/HER2- breast cancer and haven't been treated for it yet, this trial may be a good fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be hormone receptor-positive (HR+) and HER2-negative.
- Your cancer must have spread to other parts of the body (metastatic) — either when first diagnosed or later.
- You must not have received any previous treatment for metastatic breast cancer.
- You should be generally active — able to carry out daily tasks with minimal help (ECOG score 0 to 2).
- You cannot be pregnant or breastfeeding, and you should not have other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
This study uses prescription records to learn about real-world use of palbociclib (a cancer medicine). You may be included if you’re an adult and have filled at least one palbociclib prescription.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This trial tests a combination of three drugs for breast cancer that has spread and has low levels of hormone receptors. The goal is to see if this treatment can help control the cancer.
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.